Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
44°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Royalty Pharma plc - Class A Ordinary Shares
(NQ:
RPRX
)
33.97
-0.05 (-0.16%)
Streaming Delayed Price
Updated: 1:23 PM EDT, May 19, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Royalty Pharma plc - Class A Ordinary Shares
< Previous
1
2
3
Next >
Royalty Pharma Completes the Acquisition of Its External Manager
May 16, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at Upcoming Investor Conferences
May 13, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition
May 12, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Reports First Quarter 2025 Results
May 08, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Second Quarter 2025 Dividend
April 21, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025
April 17, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Vlad Coric, M.D. to the Company’s Board of Directors
April 08, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Upcoming Investor Day
March 27, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference
February 27, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces R&D Funding Collaboration With Biogen
February 12, 2025
Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Reports Q4 and Full Year 2024 Results
February 11, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
January 29, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
January 28, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
January 10, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
January 10, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Dividend Increase
January 09, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at Upcoming Investor Conferences
November 27, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
November 14, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
November 07, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Reports Third Quarter 2024 Results
November 06, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
November 04, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
October 16, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Fourth Quarter 2024 Dividend
October 11, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
September 03, 2024
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
August 28, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Reports Second Quarter 2024 Results
August 08, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
July 24, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
July 19, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Third Quarter 2024 Dividend
July 17, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
